You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Explained: UN vaccine plan for poor countries, Covax, nears roll-out

It's nearly launch time for COVAX, the United Nations' unprecedented program to deploy COVID-19 vaccines for hundreds of millions in need around the globe

United Nations | Coronavirus Vaccine


EXPLAINER: UN vaccine plan for poor countries, COVAX, nears roll-out

It's nearly launch time for COVAX, the United Nations' unprecedented program to deploy COVID-19 vaccines for hundreds of millions in need around the globe.

More than two months after countries like Britain and the United States started immunising their most vulnerable people, the U.N.'s health agency gave its approval Monday to a vaccine developed by Oxford University and AstraZeneca, which should trigger the release of hundreds of millions of doses by COVAX.

COVAX missed its own target of starting vaccination in poor countries at the same time as immunisations were rolled out in rich countries, and numerous developing countries have signed their own deals to buy vaccine, fearing the program won't deliver.

The World Health Organization and partners hope COVAX can finally start shipping out vaccines later this month.

Here's a look at the project:


It's a cooperative program aimed to make sure low- and middle-income countries get equitable access to COVID-19 vaccines. Some buy them, others get them for free thanks to donor countries and charities.

COVAX hopes to deploy some 336 million doses by the end of June, and around 2 billion doses by the end of the year.

WHO chief Tedros Adhanom Ghebreyesus said last week that over 130 million doses of vaccine have been deployed globally three quarters of them in only ten countries.

Almost 130 countries with 2.5 billion people haven't administered a single dose, he said.


Unlike most wealthy nations, many developing countries don't have the resources to assess whether vaccines should be approved.

They rely on the WHO to determine if vaccines are safe, effective and have been made properly.

The most impactful moment for COVAX so far looms with Monday's approval of the AstraZeneca vaccine; the program has bought hundreds of millions of doses, although there is no guarantee when countries will receive them.

The Serum Institute of India, which will produce the majority of them, has previously said its provision of shots to COVAX would be calibrated in line with India's own domestic and other needs.

But questions have arisen recently about the vaccine's use, given the increasing spread of the virus variant first identified in South Africa.

Early studies suggest the AstraZeneca vaccine is less effective against that variant and South Africa's government delayed plans to roll out its own supplies of the vaccine.

The WHO said last week the AstraZeneca shot should still be used in countries that have detected variants but the head of the Africa Centers for Disease Control and Prevention warned the region's countries to prioritize other vaccines instead.


COVAX leaders haven't said.

Gian Gandhi, the UNICEF supply coordinator for COVAX, said a confirmation of the doses that the U.N. children's agency can deploy will come once the WHO has approved the AstraZeneca vaccine.

The WHO takes into account readiness and need, and has placed a priority on getting doses to health care workers and vulnerable people like the elderly.

The deployment will vary from country to country," Gandhi said. In some instances, the timeframe could be in the range of days and weeks; in others it could be several weeks.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, February 16 2021. 02:54 IST